Clinical Edge Journal Scan

Atezolizumab fails to improve pCR in early TNBC


 

Key clinical point: The addition of atezolizumab to chemotherapy with nanoparticle albumin-bound nab-paclitaxel and carboplatin failed to improve pathological complete response (pCR) rates compared with chemotherapy alone in early high-risk, locally advanced, triple-negative breast cancer (TNBC).

Major finding: The rate of pCR was not significantly different between atezolizumab and non-atezolizumab treatment arms (48.6% vs. 44.4%; odds ratio 1.18; P = .48). Serious adverse events and any grade liver transaminase abnormalities were higher in the atezolizumab vs. non-atezolizumab treatment arm ( P = .001).

Study details: Findings are from the NeoTRIP study including 280 women with early high-risk, locally advanced TNBC who were randomly assigned to receive neoadjuvant carboplatin and nab-paclitaxel with or without atezolizumab.

Disclosures: This study was supported by Fondazione Michelangelo. The authors declared serving on advisory boards or receiving consulting fees, honoraria, grants, support for attending meetings, and other nonfinancial support from several sources.

Source: Gianni L et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022 (Feb 16). Doi: 10.1016/j.annonc.2022.02.004

Recommended Reading

Variants of nine breast cancer genes associated with severe disease
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: Breast Cancer March 2022
MDedge Hematology and Oncology
Should all women be routinely screened for lung cancer?
MDedge Hematology and Oncology
Oncology care model reduces cost of supportive care meds
MDedge Hematology and Oncology
Aspirin fails to inhibit breast cancer recurrence
MDedge Hematology and Oncology
15th Report on Carcinogens Adds to Its List
MDedge Hematology and Oncology
MRI with mammogram reduces breast cancer mortality by more than 50% in high-risk women
MDedge Hematology and Oncology
Heavy drinking in your 20s has lasting impact on cancer risk
MDedge Hematology and Oncology
FDA approves first PARP inhibitor for early BRCA+ breast cancer
MDedge Hematology and Oncology
TNBC: Neoadjuvant and adjuvant pembrolizumab prolongs EFS in KEYNOTE-522
MDedge Hematology and Oncology